NASDAQ:ENZY

(ENZY) (ENZY) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$11.85
$11.85
50-Day Range
N/A
52-Week Range
$6.30
$12.35
Volume
N/A
Average Volume
120,557 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ENZY stock logo

About (ENZY) Stock (NASDAQ:ENZY)

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

ENZY Stock News Headlines

What is the 72-Hour Profit Surge?
One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…
32 top US cities to have a cat
What is the 72-Hour Profit Surge?
One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…
Hello Ghost: Where to Watch & Stream Online
MyProtein Discount Codes October 2023
How To Nail The Bare Skin Movement
ENZY.ST - | Stock Price & Latest News | Reuters
See More Headlines
Receive ENZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (ENZY) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/17/2017
Today
4/26/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:ENZY
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Steve Dubin (Age 60)
    Independent Chairman of the Board
  • Erez Israeli (Age 48)
    President, Chief Executive Officer
  • Yoav Doppelt (Age 48)
    Independent Vice Chairman of the Board
  • Dror Israel (Age 46)
    Chief Financial Officer, Vice President
  • Yoav Kahane (Age 42)
    Chairman of Advanced Lipids AB
  • Yoni Twito (Age 47)
    Chief Operating Officer
  • Naama Zamir (Age 43)
    Vice President - Human Resources and Information Systems
  • Gai Ben-Dror (Age 45)
    Vice President - Process Development
  • Tzafra Cohen (Age 47)
    Vice President - Research & Development
  • Tamar D. Howson (Age 68)
    Director

ENZY Stock Analysis - Frequently Asked Questions

How were (ENZY)'s earnings last quarter?

(ENZY) (NASDAQ:ENZY) issued its quarterly earnings data on Wednesday, May, 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.03. The biotechnology company earned $12 million during the quarter, compared to analysts' expectations of $14.23 million. The business's revenue was down 14.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.09 earnings per share.

What other stocks do shareholders of (ENZY) own?
This page (NASDAQ:ENZY) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners